… 47 studies were eligible from 38 countries across six continents. 28 and 12 … Evidence
from this network meta-analysis could help to guide vaccination strategies, and we recommend …

… of the 13-valent PCV (PCV13) and 10-valent PCV (PCV10) in … a safe and effective preventative
measure for pediatric use. … (INB) stratified by country income level, study perspective, and …

… among US adults based on safety and immunogenicity data … recommended 13-valent
pneumococcal conjugate vaccine (… in other countries. Post-licensure effectiveness and impact …

… The limitation with this approach is that VE estimates are dependent on the pre-existing
proportion of vaccine and non-vaccine serotypes in the study country which differ across …

… countries included 2 primary doses with a booster (n = 13) … ; PCV13, 13-valent pneumococcal
conjugate vaccine; PCV10, … While clinical trial data suggest a minimal difference between …

… and may be influenced by outliers in a clinical trial. For these reasons, reverse cumulative …
cases in children and adults in countries where PCVs are included in the infant immunization …

… A placebo-controlled clinical trial (CAPiTA) showed that … in several countries worldwide;
however, few countries have … Each 0.5 mL dose contains 2.2 µg 1, 3, 4, 5, 6A, 7F, 9 V, 14, 18C…

… on countries graduating from support for vaccine purchase … 13-valent PCV (Prevenar13®,
Pfizer® [PCV13]) in toddlers … and Tropical Medicine—in clinical trial facilities in the peri-urban …

… in nations with successful PCV national infant immunization … a subset of vaccinated children
in some or all clinical studies.[79… - use of 13-valent pneumococcal conjugate vaccine and 23-…

… vaccination of 13-valent pneumococcal conjugate vaccine (… protection against pneumococcal
disease in some countries. … volunteers enrolled in preventive vaccine clinical trials; 2007. …